Procter & Gamble (PG) Offering Possible 31.93% Return Over the Next 20 Calendar Days

Procter & Gamble's most recent trend suggests a bearish bias. One trading opportunity on Procter & Gamble is a Bear Call Spread using a strike $138.00 short call and a strike $143.00 long call offers a potential 31.93% return on risk over the next 20 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $138.00 by expiration. The full premium credit of $1.21 would be kept by the premium seller. The risk of $3.79 would be incurred if the stock rose above the $143.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Procter & Gamble is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Procter & Gamble is bearish.

The RSI indicator is at 44.98 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Procter & Gamble

Could Kimberly-Clark Be a Millionaire-Maker Stock?
Mon, 07 Sep 2020 13:38:00 +0000
Investors love the consumer staples industry because of the steady growth it can deliver to its biggest players. It might not be exciting, but the profit stream from selling essentials like tissues and diapers is durable and has made many millionaires out of long-term holders of companies like Procter & Gamble (NYSE: PG) and Colgate-Palmolive (NYSE: CL). Kimberly-Clark (NYSE: KMB) stock has trailed the market's returns over the past five years.

The Top 5 Buys of the MS Global Franchise Fund
Fri, 04 Sep 2020 22:25:28 +0000
Fund releases 2nd-quarter portfolio

Forget Clorox, Procter & Gamble Is a Better Consumer Staples Stock
Fri, 04 Sep 2020 16:45:00 +0000
Clorox generated big gains throughout the pandemic, but its old problems could surface after the crisis ends.

The Dow Jones Index: The Story Of COVID-19 Winners
Fri, 04 Sep 2020 16:20:27 +0000
Despite not including electrifying stocks such as Amazon.com, Inc. (NASDAQ: AMZN), and therefore missing out on its historical gains, the Dow Jones Index still has quite a few winners under its umbrella. Although Apple Inc (NASDAQ: AAPL) and Microsoft Corporation (NASDAQ: MSFT) had their worst-performing days since March yesterday, the drop was followed by their peers Facebook, Inc. (NASDAQ: FB), Alphabet Inc (NASDAQ: GOOG) and Amazon. One bad day cannot erase the massive rally of these tech stocks which literally bloomed throughout the pandemic, or more precisely, the first two quarters of the year.Apple shares rose nearly 70% to date with the market value surpassing a $2 trillion market cap. Moreover, Apple is no longer dependent on its 'sacred cash cow', iPhone, as it showed it is successfully reshaping its business model to services. But even the iPhone is doing well, as Omdia's research showed that iPhone 11 was the most popular smartphone during the first half of 2020.Microsoft's latest revenue of $38 billion exceeded expectations of $35.5 billion. Earnings per share of $1.46 exceeded the estimate of $1.36. If we look at Intelligent Cloud alone, revenue amounted to $13.4 billion. The story of Microsoft's rebirth is greatly owed to its Intelligent Cloud business. During the fourth quarter, Intelligent Cloud brought in a revenue of $13.4 billion. This a 17% increase compared to the same quarter last year. If the pandemic has shown us anything is that tech is crucial for business resilience and faster recovery. Coca-Cola Co (NYSE: KO) and Walgreens Boots Alliance Inc (NASDAQ: WBA) also turned to Microsoft for its simplicity and seamless integration.Microsoft's gaming business also saw skyrocketing growth of 64%, amounting to 1.3 billion, as Xbox hardware revenue jumped 49%. The Xbox Series X is also coming in November. Microsoft has over a billion enterprise users and it can be found in nearly every enterprise of the planet. From early March to the end of April, Microsoft Teams grew from 11 million to over 75 million users. Users want systems that can work together without complexity and Microsoft delivered on that promise.Although AstraZeneca plc (NYSE: AZN) is the leader in the vaccine race, Johnson & Johnson (NYSE: JNJ) has ample financial resources along with an array of brands to boost its chances. Yesterday, Reuters reported that Johnson & Johnson announced its coronavirus vaccine prevented hamsters from getting severely ill. Although we need to wait for human trials to begin next month, this is something to be excited about. Its pharmaceutical segment still stood strong amid the devastating second quarter. Despite falling earnings, the company continued to pay dividends. Johnson & Johnson is a Dividend Aristocrat, a company that not only continuously pays dividends but also keeps increasing them. The bottom line is that it is diversified enough to survive the storm while also expecting to expand earnings for fiscal 2020 despite delivering losses in the second quarter.Despite the focus on performance chemicals, Dow Inc (NYSE: DOW) portfolio is actually quite diversified. During the second quarter, some of Dow's sales did suffer as it was the worst quarter of the year all over the globe. But despite plummeting sales of big items such as new homes, furniture, and cars, sales of cleaning and disinfecting products, which also use Dow's chemicals, increased. People started cooking at home, increasing the demand for food packaging. Professional construction chemical sales dropped, but do-it-yourself home improvement rose and pulled paints and coatings along. This diversified portfolio allowed Dow to outperform expectations. More importantly, it generated plenty of cash to fund its dividend.Pharma titan Merck & Co., Inc. (NYSE: MRK) and recently expelled from the Dow, Pfizer Inc. (NYSE: PFE), appear to be two of the most evenly matched competitors in the pharmaceutical sector. But unlike Merck, Pfizer is limping besides the pandemic creating an opportunity for a vaccine. Merck also has two vaccine candidates. Chief executive Kenneth Frazier announced on Thursday that human testing is starting fairly soon. Over the last half of a decade, Merck's stock has consistently outperformed Pfizer's. Merck's value grew by 6% whereas Pfizer's dropped 3.1%.Over the next three years, Merck will invest $19 billion into expanding its oncology, vaccine, and animal health segments. Its cancer immunotherapy is expected to continue fueling its sales as Keytruda sales were 46% year-over-year.The Procter & Gamble Co (NYSE: PG) had its best fiscal year in more than a decade. Despite all of us being germ-conscious in this new pandemic era, we still have cravings such as donut and coffee. Procter & Gamble has already teamed up with Dunkin' Brands Group Inc (NASDAQ: DNKN) owned Dunkin' Donuts to promote the use of its cleaning products in restaurants, but it is looking for more partners with fast-food, hospitality, transportation and healthcare companies. At the end of the day, it's more than revenue- it's free publicity. Sales gains managed to beat management's target for the fourth consecutive quarter, and cash flow and profitability reached new highs. But most importantly, the outlook is even brighter with further market share expansion. Fiscal 2020 results are evidence that P&G can invest aggressively in growth strategies while still boosting profitability.So, there you have it. Big Tech, medical devices, pharmaceutical and consumer goods Dow winners of the pandemic. And there's no reason to doubt that the post-COVID era will be just as kind to them as they provided meaningful service and products that actually made a difference during these unprecedented circumstances.This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure . IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you're interested in becoming an IAM journalist contact: contributors@iamnewswire.comThe post The Dow Jones Index – The Story of COVID-19 Winners appeared first on IAM Newswire.Photo by Annie Spratt on UnsplashSee more from Benzinga * 4 Solar Stocks That Could Be Even Better Than Tesla * Big Tech: Too Much Value Concentrated In Only A Few Ecosystems * 3 Cannabis Stocks That Are Well Positioned To Benefit From Industry Growth(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Top 10 S&P 500 Stocks by Index Weight
Fri, 04 Sep 2020 00:06:30 +0000
These are the top 10 most heavily weighted stocks in the S&P 500 Index. See which stocks fell in the rankings, and which rose.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.